ACTA1 and Hepatic fibrosis: One of the PPAR-γ agonists (rosiglitazone) has been reported to prevent murine hepatic fibrosis, which was accompanied by the induction of the expression of TNF-α and IL-6 but a reduction of the expression of TGF-β1 and α-SMA in liver tissue [10].